# Kwality Pharmaceuticals share price today (Kwality Pharmaceuticals Ltd, NSE: KPL) > Kwality Pharmaceuticals share price today: ₹4,207.90 at the NSE close on 18 November 2026, up 345.7% in a year. Kwality Pharmaceuticals (NSE: KPL) is worth ₹4,365 crore, trades at a P/E of 45.5 and has closed between ₹895.70 and ₹4,207.90 over the past 52 weeks. > Kwality Pharmaceuticals Ltd's share price has risen faster than its earnings: +345.7% in a year, against +69.0% for earnings per share. KPL · Pharma - Formulators · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Growing steadily, from the last 12 quarters - Price: ₹4,207.90 (+345.7% in a year) - P/E: 45.5× (higher than 98% of the last 10 years) - Revenue (Sep 2026): ₹181 Cr (+63.1% on a year ago) - Profit (Sep 2026): ₹29.0 Cr (+107.1% on a year ago) - Operating margin: 27.6% (+5.1 points on a year ago) - ROCE: 24%, FY26 - ROIC: 21.2%, against a 12.0% cost of capital: +9.2 points The main question: the share price moved +345.7% in a year while yearly earnings per share moved +69.0%. The difference came from the market paying a higher multiple. ## What is the Kwality Pharmaceuticals share price today? Kwality Pharmaceuticals Ltd's share price was ₹4,207.90 at the close on 18 November 2026. It has been rising for 47 weeks. That is 58.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹896 and ₹4,208, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 44 weeks in a row. Over the last 10 years the share price moved +18,602% while the NIFTY 500 moved +228%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Kwality Pharmaceuticals this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), best operating margin in 15 quarters and profit up on a year earlier for 10 quarters in a row. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹181 crore, +63.1% on a year earlier. 2. Best operating margin in 15 quarters Operating margin was 27% in the September 2026 quarter, against 23% a year earlier. 3. Profit up on a year earlier for 10 quarters in a row In the September 2026 quarter profit was ₹29 crore, +107.1% on a year earlier. ## What are Kwality Pharmaceuticals' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Kwality Pharmaceuticals reported revenue of ₹181 crore, up 63.1% from ₹111 crore a year earlier, and a profit of ₹29.0 crore, up 107.1% from ₹14.0 crore. ### Kwality Pharmaceuticals results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹181 crore | ₹111 crore | +63.1% | | Profit | ₹29.0 crore | ₹14.0 crore | +107.1% | | Earnings per share | ₹27.98 | ₹13.61 | +105.6% | | Operating margin | 27.6% | 22.5% | +5.1 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Kwality Pharmaceuticals' management discussed these results on a call held on 13 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Kwality Pharmaceuticals share price history? Kwality Pharmaceuticals closed at ₹4,207.90 on 18 November 2026, up 345.7% from ₹944.10 a year earlier (21 November 2025) and up 412.1% over five years. Its highest weekly close since July 2016 was ₹4,207.90 on 18 November 2026. ### Kwality Pharmaceuticals share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹3,983.80 | +5.6% | | 1 month ago · 19 Oct 2026 | ₹3,366.00 | +25.0% | | 6 months ago · 15 May 2026 | ₹1,719.20 | +144.8% | | 1 year ago · 21 Nov 2025 | ₹944.10 | +345.7% | | 3 years ago · 17 Nov 2023 | ₹340.70 | +1,135.1% | | 5 years ago · 18 Nov 2021 | ₹821.75 | +412.1% | | 10 years ago · 17 Nov 2016 | ₹29.35 | +14,237.0% | | Earliest weekly close in our records · 22 Jul 2016 | ₹22.50 | +18,601.8% | | Highest weekly close since July 2016, also the 52-week high · 18 Nov 2026 | ₹4,207.90 | 0.0% | | Lowest weekly close since July 2016 · 16 Dec 2019 | ₹21.30 | +19,655.4% | | 52-week low (weekly close) · 5 Dec 2025 | ₹895.70 | +369.8% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (463 weekly closes from 22 July 2016 to 18 November 2026.) ## What is the latest news on Kwality Pharmaceuticals? 18 Nov 2026: Kwality Pharmaceuticals closed at ₹4,207.90, up 5.6% on the week and up 25.0% on the month. 13 Nov 2026: Kwality Pharmaceuticals held its results call for July to September 2026. ### Earlier - Results for July to September 2026: Revenue up 63.1% and profit up 107.1% on a year earlier. ## What dividend does Kwality Pharmaceuticals pay? Kwality Pharmaceuticals has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Kwality Pharmaceuticals Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Kwality Pharmaceuticals management say on the latest results call? On the call for July to September 2026, held on 13 November 2026, Kwality Pharmaceuticals' management spoke about the quarter; the main points are below. Source: [the call transcript](https://files.tijorifinance.com/insight/india/26654/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 13 November 2026.) ## What to watch in Kwality Pharmaceuticals' next results? When Kwality Pharmaceuticals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +63.1% on a year earlier, and the last four quarters averaged +47.7%. - Whether the operating margin stays near 27.6%. It is 5.1 percentage points higher than four quarters earlier. - Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +107.1% on a year earlier. It has grown on a year earlier for 10 quarters in a row. ## Which stock lists is Kwality Pharmaceuticals on? Kwality Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market value: ₹4,198 crore](https://www.sectoralpha.in/momentum-stocks-india) - [Pharma stocks Market value: ₹4,198 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Kwality Pharmaceuticals profitable? Kwality Pharmaceuticals Ltd earned ₹29.0 Cr of net profit in the Sep 2026 quarter, +107.1% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹67.0 Cr. Over 10 years profit has grown 52.3% a year on average. The same quarter a year earlier earned ₹14.0 Cr. The Sep 2026 quarter's profit is 16.0% of that quarter's revenue. For the full year, FY26 profit was ₹67.0 Cr (+67.5% on the year before). Why profit moved: revenue changed +63.1% on a year earlier and the margin moved +5.1 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +95.0% and revenue +47.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Kwality Pharmaceuticals make, and is it growing? Kwality Pharmaceuticals Ltd reported ₹181 Cr of revenue in the Sep 2026 quarter, +63.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 21.1% a year on average. The last full year, FY26, came in at ₹503 Cr. Why this happened. The near-term revenue driver. Regulated export markets carry 2-3× the realization of domestic generics. Management's H1 FY26 baseline is ₹60-70 Cr from these three markets; the FY27 guide is ₹200 Cr incremental (implying ₹260-270 Cr from these markets alone in FY27). The 40+ bioequivalence programs and 400-500 out-licensed molecules across 30-40 countries build the long-term distribution moat. The short-term proof point is whether Q1 FY27 revenue shows the ₹50 Cr+ run-rate from these geographies. The last four reported quarters add to ₹623 Cr. FY26 revenue was ₹503 Cr, +35.9% on the year before. Recent pace: the last four quarters grew +47.7% on average, against 21.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +47.6%, against +35.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +95.9%, against +85.2% a year (accelerating). ## How much of every ₹100 of sales does Kwality Pharmaceuticals keep? Kwality Pharmaceuticals Ltd's operating margin was 27.6% in the Sep 2026 quarter, 5.1 percentage points higher than the same quarter a year ago. Across 13 years it has been between 5.8% and 37.7%. The latest quarter is within that range. Why this happened. The core driver. Kwality's move to regulated markets (EU-GMP, PIC/S certified) unlocks higher pricing on the same manufacturing base. The OPM expansion from 21% to 24% reflects both mix shift (regulated export premium) and operating leverage on fixed cost. The FY27 guide of 25-26% EBITDA implies another 100-200bps of expansion, supported by biosimilar/biologic mix shift, which carries structurally higher margins than commodity generics. The revenue trajectory is the cleanest signal: 4 consecutive acceleration quarters, with Dec 2025 quarter at ₹123 Cr vs Dec 2024 ₹84 Cr (+46.4% YoY). Why the margin moved: operating margin changed +4.7 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Kwality Pharmaceuticals' profit turning into cash? Over the last 3 years, 86% of Kwality Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹17.0 Cr of operating cash against ₹67.0 Cr of profit. After ₹45.0 Cr of spending on assets, free cash was −₹28.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 86% of profit came in as cash: the cash cycle got 140 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building. ## Where does Kwality Pharmaceuticals' cash go? Kwality Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 170 days in FY26, up from 30 days in FY21. It spent ₹98.0 Cr on assets over the last 3 years. Customers take 203 days to pay, and stock sits for 111 days on average. At FY26 sales of ₹503 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹234 Cr is tied up in the business at any time. FY26: customers took 203 days to pay and stock sat for 111 days, about 3.7 months of sales sitting as stock, for a full cycle of 170 days, longer than FY21's 30. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 111 days. Customers pay about 203 days after that. Suppliers are paid at 144 days. Together that makes the 170-day cycle. Spending on assets: ₹98.0 Cr over the last 3 years, against ₹58.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹17.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Kwality Pharmaceuticals' P/E ratio, and how does it compare with its own history? Kwality Pharmaceuticals Ltd's P/E is 45.5×, about the highest it has ever been. Its usual P/E (the middle reading) is 15.8×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +69.0% while the price moved +345.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +38.6% a year; about −1.1% a year came from earnings growth and about +39.7 percentage points from the multiple (the market paying more); over 10 years the price moved +64.3% a year; about +49.4% a year came from earnings growth and about +14.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Kwality Pharmaceuticals business getting better or worse? Kwality Pharmaceuticals Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 37.9% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the Kwality Pharmaceuticals story, and has it been checked? Kwality Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: fully expanded. Still open: Revenue miss (₹124 vs ₹140 Cr), Unit 6 CWIP=0 contradiction, US market strategic pivot, Africa subsidiary exit, all surfaced in a single Feb 2026 concall. Our read, 17 May 2026. A commodity-generics formulator mid-leap into regulated-market exports and biologics, 4-quarter momentum validates the move; management credibility under watch. From the numbers. From the price. Price stage 2, week 47, above its 200-day line, relative strength falling. Where they disagree. The current reading at 24.45 is approaching the 2017 peak level. EPS trajectory is the positive counter: ₹11.50 → ₹13.61 → ₹15.43 across Q1-Q3 FY26. What is not proven yet. Revenue miss (₹124 vs ₹140 Cr), Unit 6 CWIP=0 contradiction, US market strategic pivot, Africa subsidiary exit, all surfaced in a single Feb 2026 concall. The test written in advance. Management credibility, 4 documented consistency failures. Measured by: Management credibility, 4 documented consistency failures Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet by the next result. The test written in advance. OPM vs 24% Dec quarter benchmark by the next result. The test written in advance. Biologic execution, first-time EPO launch risk. Measured by: Biologic execution, first-time EPO launch risk Clinical trial commencement April 2027; interim export announcement H1 FY27 by the next result. What the company does. Revenue accelerated 4 consecutive quarters (YoY: +26%, +39%, +23%, +46%), OPM expanded from 21% to 24%, TTM PAT +93%, the inflection is real. Management's FY27 PAT goal of ₹100 Cr (vs TTM ~₹56 Cr) is bold; Erythropoietin biologic launch and Mexico/Colombia registrations are the next proof points. Lever 1 · Operating leverage: building. Revenue +26/39/23/46% YoY over 4 quarters; OPM 21→22→23→24%, operating leverage converting revenue growth to PAT +93% TTM. What proves it keeps working: Operating Leverage Inflection. It stops working if Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet. Lever 5 · Regulatory approval: building. First biologic launch, EPO pre-clinical approved, clinical trials April 2027, interim export H1 FY27; biologic mix structurally expands OPM to 29-30% by FY29. What proves it keeps working: Biologic Launch, Erythropoietin (EPO). Lever 10 · New geographies: building. Mexico/Colombia/Algeria registrations moving to commercialization, management guides ₹200 Cr incremental FY27 from these 3 markets alone (vs H1 FY26 baseline of ₹60-70 Cr from all 3 combined). What proves it keeps working: Geographical Expansion, Regulated Markets (Mexico, Colombia, Algeria). Lever 7 · Consolidation: building. CCC goal 170-180 days from ~280 days, inventory optimization and mix shift to higher-paying markets (Mexico/Colombia) releasing capital; ROCE trajectory improving. What proves it keeps working: Working Capital Normalization. Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Kwality Pharmaceuticals management deliver what it promised? What Kwality Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. EPO Regulatory Pathway Reversed · 13 November 2026. In Aug 2026, management said the Erythropoietin dossier could lead to registrations in 10-12 ROW countries after the first four-month study, without waiting for complete clinical trials. In Nov 2026, management said formal registration is subject to clinical studies and only temporary supplies may be made under a biowaiver. This changes the regulatory basis and timing of the EPO revenue case, rather than merely refining the launch schedule. BE Program FY29 Revenue Estimate Cut · 13 November 2026. In Aug 2026, management projected at least INR400 crores to INR500 crores of FY29 revenue from the BE program. In Nov 2026, management instead described FY29 revenue of only 250-300 crores for the product group discussed, despite the earlier 40-BE program scope. The latest call does not reconcile this materially lower estimate with the prior program assumptions. Debtor-Day Progress Reversed · 13 November 2026. In Aug 2026, management expected debtor days to settle at 165-170 days and planned 155-160 days in regular operations. In Nov 2026, management reported debtor days of 178 days, above both the prior current range and the stated operating goal. Although the latest call described the overall working capital cycle as improved and said Middle East receivables had been realized, it did not explain why debtor days moved away from the earlier goal. Saudi and GCC Growth Thesis Deprioritized · 13 November 2026. In Aug 2026, management positioned Saudi Arabia and the broader GCC as the next geographic growth venue, with revenue expected by the end of the third quarter. In Nov 2026, management said Saudi Arabia, Iraq, and Iran were slow-moving and were no longer a significant focus, shifting future emphasis to Latin America and Europe. Although slow-moving markets were cited as the reason, management did not reconcile this strategic reversal with the earlier expected Saudi and GCC revenue ramp. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Kwality Pharmaceuticals earn on its capital? Kwality Pharmaceuticals Ltd earned a ROCE of 24% in FY26. That is up from a low of 9% in FY15. Its return on capital used (ROIC) is 9.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.3% net margin and 0.85× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.3% net margin × 0.85× asset turnover × 1.79× leverage (assets divided by equity) ≈ 20.2% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 21.2% − 12.0% = +9.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 21.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 18.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Kwality Pharmaceuticals have too much debt? Kwality Pharmaceuticals Ltd has total debt of ₹146 Cr against shareholder equity of ₹386 Cr as of Sep 2026, so its debt is 0.38× its equity. Year by year, that ratio went from 0.35 in FY22 to 0.40 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Kwality Pharmaceuticals shareholding pattern? Foreign institutions raised their stake in Kwality Pharmaceuticals Ltd by 2.5 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.5% of the company. Domestic institutions moved +1.1 points over the same period, to 1.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +2.5 points over 8 quarters, to 2.5%; Domestic institutions: +1.1 points over 8 quarters, to 1.1%; Promoters: +0.0 points over 8 quarters, to 54.9%. Why the owners changed: foreign institutions drove it (+2.5 points), together with domestic institutions (+1.1 points). They raised their stake step by step. ## How far is Kwality Pharmaceuticals from balance-sheet trouble? For Kwality Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. Why this happened. The strategic step-change catalyst. EPO (Erythropoietin) is the company's first biosimilar, with a clear regulatory pathway: interim export beginning June-July 2027, India commercialization August 2027. Management's guide to 40+ bioequivalence programs and five CDMO partnerships with European innovators creates a pipeline overlay. The biologic thesis is incremental margin, not incremental volume, a single biologic molecule in the oncology/biosimilar segment can contribute at 35-40% gross margin vs the 24% current blended OPM. This is the driver underpinning the FY29 margin guide of 29-30%. Risk: first-time biologics execution, regulatory approval uncertainty, clinical trial timeline. ## How does Kwality Pharmaceuticals rank in its industry? 68.3 out of 100, rank 3 of 44 in Pharma - Formulators, with 75% of the evidence available. Kwality Pharmaceuticals Ltd scores 68.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 3. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 32.5 + 17 + 6.5 + 12.3 = 68.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Kwality Pharmaceuticals compared with? Kwality Pharmaceuticals ranks 3 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 68.3 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. Kwality Pharmaceuticals Ltd this page KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Kwality Pharmaceuticals in size? Kwality Pharmaceuticals is the 29th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Suven Life Sciences, Bliss GVS Pharma and FDC. Just below it: Gufic BioSciences, RPG Life Sciences and Fredun Pharmaceuticals. ### Pharma - Formulators companies close in size 1. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,507 crore 2. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹7,238 crore 3. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) ₹6,087 crore 4. Kwality Pharmaceuticals Ltd ₹4,366 crore 5. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) ₹4,235 crore 6. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) ₹4,139 crore 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) ₹2,802 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [West Coast Paper Mills Ltd](https://www.sectoralpha.in/stocks/west-coast-paper-mills-ltd) ₹4,380 crore · Paper 2. [V-Marc India Ltd](https://www.sectoralpha.in/stocks/v-marc-india-ltd) ₹4,372 crore · Cables - Power 3. Kwality Pharmaceuticals Ltd ₹4,366 crore 4. [Saatvik Green Energy Ltd](https://www.sectoralpha.in/stocks/saatvik-green-energy-ltd) ₹4,357 crore · Electric Equipment - General 5. [Juniper Hotels Ltd](https://www.sectoralpha.in/stocks/juniper-hotels-ltd) ₹4,335 crore · Hotels ## What else do people ask about Kwality Pharmaceuticals? ### What is Kwality Pharmaceuticals's share price today? Kwality Pharmaceuticals Ltd's share price is ₹4,207.90, +345.7% over the past year. The whole company is worth ₹4,365 Cr on the market. It is at its highest price of the past 52 weeks (range ₹896 to ₹4,208), 58.3% above its 200-day average. The price has been rising for 47 weeks (as of 18 November 2026). ### What were Kwality Pharmaceuticals's latest quarterly results? Kwality Pharmaceuticals Ltd reported revenue of ₹181 Cr and net profit of ₹29.0 Cr for the Sep 2026 quarter. Revenue rose 63.1% and profit rose 107.1% compared with a year earlier. Earnings per share were ₹27.98. The operating margin was 27.6%, 5.1 percentage points higher than a year earlier (as of 18 November 2026). ### What is Kwality Pharmaceuticals's market cap? Kwality Pharmaceuticals Ltd's market capitalisation is ₹4,365 Cr at a share price of ₹4,207.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Kwality Pharmaceuticals performing? Kwality Pharmaceuticals Ltd's share price has been rising for 47 weeks. In its latest quarter, revenue rose 63.1% and profit rose 107.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 44 weeks running (as of 18 November 2026). ### Will Kwality Pharmaceuticals's share price go up? This page does not forecast Kwality Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹4,207.90, and it has been rising for 47 weeks. Its P/E of 45.5× is higher than 98% of its own last 10 years (as of 18 November 2026). ### Who owns Kwality Pharmaceuticals? Promoters own 54.9% of Kwality Pharmaceuticals Ltd, foreign institutions 2.5%, domestic institutions 1.1% and the public 41.6% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 2.5 percentage points over 8 quarters (as of 18 November 2026). ### Does Kwality Pharmaceuticals have too much debt? Kwality Pharmaceuticals Ltd has a moderate amount of debt: its debt is 0.39× its equity, and its operating profit is 11 times its interest bill. FY26 borrowings were ₹130 Cr against equity of ₹331 Cr. Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026). ### Where is Kwality Pharmaceuticals in its business cycle? Kwality Pharmaceuticals Ltd's FY26 operating margin was 23.5%, against a 13-year range of 5.8% to 37.7%. The latest quarter was 27.6%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Kwality Pharmaceuticals story? The main question: the share price moved +345.7% in a year while yearly earnings per share moved +69.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Kwality Pharmaceuticals a stock worth studying right now? What the numbers show: Kwality Pharmaceuticals Ltd's share price has risen faster than its earnings: +345.7% in a year, against +69.0% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.